Macrophages play an important role during Mycobacterium tuberculosis (MTB) infection. In humans most of the studies on MTB-macrophage interactions have been performed using circulating monocytes and monocyte-derived macrophages. However, little research has been performed on this interaction using tissue macrophages. Herein, we used human splenic macrophages to characterize particular responses to MTB infection. Based on morphological, biochemical, and immunological markers, splenic adherent cells exhibit characteristics of tissue macrophages. They were able to efficiently phagocytose both live and heat-killed (h-k) MTB H37Rv. Upon infection with live, but not h-k MTB, an increase in secreted TNF-alpha was elicited. Splenic macrophages produced high basal levels of IL-10; however, infection with live or h-k MTB resulted in decrease IL-10 secretion. Both IL-12p40 and IL-12p70 basal levels were also decreased upon infection with live or h-k MTB; however, while the reduction for IL-12p40 levels was observed at earlier time points (4h) for both live and h-k MTB, infection with live MTB, but not h-k MTB, resulted in a time-dependent secretion of IL-12p40 at 24 and 48h after infection. IL-12p70 levels were completely reduced upon infection by either live or h-k MTB. These results support that human splenic macrophages may represent a potential useful model to study MTB-macrophage interactions in vitro.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.tube.2007.07.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial.
Blood Adv
April 2024
Department of Internal Medicine, Ulm University Hospital, Ulm, Germany.
Guadecitabine is a novel hypomethylating agent (HMA) resistant to deamination by cytidine deaminase. Patients with relapsed/refractory acute myeloid leukemia (AML) were randomly assigned to guadecitabine or a preselected treatment choice (TC) of high-intensity chemotherapy, low-intensity treatment with HMAs or low-dose cytarabine, or best supportive care (BSC). The primary end point was overall survival (OS).
View Article and Find Full Text PDFResponse to anti-IL17 therapy in inflammatory disease is not strongly impacted by genetic background.
Am J Hum Genet
October 2023
Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK. Electronic address:
Response to the anti-IL17 monoclonal antibody secukinumab is heterogeneous, and not all participants respond to treatment. Understanding whether this heterogeneity is driven by genetic variation is a key aim of pharmacogenetics and could influence precision medicine approaches in inflammatory diseases. Using changes in disease activity scores across 5,218 genotyped individuals from 19 clinical trials across four indications (psoriatic arthritis, psoriasis, ankylosing spondylitis, and rheumatoid arthritis), we tested whether genetics predicted response to secukinumab.
View Article and Find Full Text PDFOutcomes among trauma patients with duodenal leak following primary versus complex repair of duodenal injuries: An Eastern Association for the Surgery of Trauma multicenter trial.
J Trauma Acute Care Surg
July 2023
From the Rutgers Robert Wood Johnson Medical School (R.L.C., A.L.T., C.G.B.), New Brunswick, New Jersey; Grady Memorial Hospital (J.D.S., R.N.S., D.S. Hanos), Atlanta, Georgia; Temple University Hospital (I.N.A., J.H.B.), Philadelphia, Pennsylvania; R Adams Cowley Shock Trauma Center (N.K.D., A.Z., M.G.), University of Maryland School of Medicine, Baltimore, Maryland; Vanderbilt University Medical Center (R.J.D., O.L.G.), Nashville, Tennessee; Louisiana State University Health Sciences Center (A.A.S., B.L.S.), New Orleans, Louisiana; University of Kentucky (C.S.C., J.K.R.), Lexington, Kentucky; Medical College of Wisconsin (L.A.H., D.N.H.), Wauwatosa, Wisconsin; Mount Sinai Hospital (G.C., M.J.), Chicago, Illinois; Cooper University Hospital (K.E., N.S.F.), Camden, NJ; Indiana Health Methodist Hospital (A.A., J.H.L.), Indianapolis, India; University of Texas Southwestern (R.P.D., C.A.F.), Dallas, Texas; MEDStar Washington Hospital Center (C.T.T., J.J.Y.), Washington, DC; Perelman School of Medicine (J.B.), University of Pennsylvania, Philadelphia, Pennsylvania; Penn State Hershey Medical Center (J.H., C.J. McLaughlin), Hershey, Pennsylvania; Washington University School of Medicine/Barnes-Jewish Hospital (R.A.-A., J.M.K.), St. Louis, Missouri; Boston Medical Center (D.S. Howard, D.R.S.), Boston, Massachusetts; University of Rochester (K.D., M.V.), Rochester, New York; McGill University (B.H., E.G.W.), Montreal, Quebec, Canada; WakeMed Health and Hospital (C.S., P.O.U.), Raleigh, North Carolina; University of Arizona (B.A.J.), Tuscon, Arizona; Jackson Memorial Hospital Ryder Trauma Center (H.L., W.R.), Miami, Florida; University of Arizona (C.H.S.), Tuscon, Arizona; University of California Irvine Medical Center (C.A., J.N.), Orange County, California; Broward Health Medical Center (J.D.B., I.P.), Fort Lauderdale, Florida; Henry Ford Hospital (J.H.P., I.R.), Detroit, Miami; Penn Medicine Lancaster General Hospital (L.L.P., O.R.P.), Lancaster, Pennsylvania; Yale New Haven Hospital (H.A., L.M.K.), New Haven, Connecticut; Hartford Hospital (J.K., J.W.), Hartford, Connecticut; Oregon Health and Science University (R.H., M.A.S.), Portland, Oregon; University of Chicago Medicine and Biological Science (A.J.B., A.K.), Chicago, Illinois; Spartanburg Medical Center (L.K.M., C.J. Mentzer), Spartanburg, South Carolina; General University Hospital of Patras (V.M., F.M.), Patras, Achaia, Greece; Thomas Jefferson University Hospital (S.R.-G., E.S., J.M.), Philadelphia, Pennsylvania; South Texas Health System McAllen Medical Center (C.F., C.H.P.), McAllen, Texas; Massachusetts General Hospital (D.A., H.K.), Boston, Massachusetts; Rutgers Robert Wood Johnson Medical School (S.C., M.M.), New Brunswick, New Jersey; Rutgers School of Public Health (M.T.B.M.), Piscataway, New Jersey; Rutgers Robert Wood Johnson Medical School (M.N.), New Brunswick, New Jersey; and Perelman School of Medicine (M.J.S.), University of Pennsylvania, Philadelphia, Pennsylvania.
Background: Duodenal leak is a feared complication of repair, and innovative complex repairs with adjunctive measures (CRAM) were developed to decrease both leak occurrence and severity when leaks occur. Data on the association of CRAM and duodenal leak are sparse, and its impact on duodenal leak outcomes is nonexistent. We hypothesized that primary repair alone (PRA) would be associated with decreased duodenal leak rates; however, CRAM would be associated with improved recovery and outcomes when leaks do occur.
View Article and Find Full Text PDFGenetic Variants Close to , , and Associate With AVNRT.
Circ Res
October 2022
Laboratory for Molecular Cardiology, Copenhagen University Hospital - Rigshospitalet, Copenhagen Denmark Molecular Cardiology, Cardiology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark (L.A., G.A., P.R.L., J.P.H., C.P.-M., K.H.-T., J.G., S.H., J.H.S., M.S.O.).
Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy.
NPJ Precis Oncol
September 2022
WIN Consortium for Precision Medicine, Paris, France.
Despite remarkable responses to immune checkpoint blockade (ICB) in some advanced cancers, most patients do not benefit, perhaps due to the complexity of tumor/immune/genome interactions. We implemented a multidisciplinary Molecular Tumor Board (MTB) that reviewed multi-omic cancer characteristics to develop N-of-One therapies for patients in the pan-cancer, advanced, refractory setting. This study evaluates the experience of 80 patients who were presented to the MTB and received a treatment regimen that included ICB.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!